Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients

Multiple Sclerosis

Volumn 16, Issue 8, 2010, Pages 942-949

  Enevold, Christian ^a   Oturai, Annette B ^b   Sørensen, Per Soelberg ^b   Ryder, Lars P ^b   Koch Henriksen, Nils ^b,c   Bendtzen, Klaus ^a  

^a Rigshospitalet   (Denmark)

^b Rigshospitalet   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

gender; interferon beta; multiple sclerosis; neutralizing antibodies; pattern recognition receptors; single nucleotide polymorphism; toll like receptors

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; PATTERN RECOGNITION RECEPTOR; RECOMBINANT BETA INTERFERON; TOLL LIKE RECEPTOR;

ADOLESCENT; ADULT; ANTIBODY PRODUCTION; ARTICLE; DISEASE ACTIVITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATTERN RECOGNITION; POLYMERASE CHAIN REACTION; RELAPSE; REMISSION; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; DEAD-BOX RNA HELICASES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON TYPE I, RECOMBINANT; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NOD1 SIGNALING ADAPTOR PROTEIN; NOD2 SIGNALING ADAPTOR PROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, INTERFERON ALPHA-BETA; SEX FACTORS; TOLL-LIKE RECEPTOR 6; TOLL-LIKE RECEPTORS; YOUNG ADULT;

EID: 77955164022     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510373264     Document Type: Article

References (69)

1. Compston A. and Coles A. Multiple sclerosis. Lancet 2008 ; 372: 1502-1517.
2. Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1997 ; 49: 358-363.
3. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
4. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
5. Goodin DS, Frohman EM, Hurwitz B., et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007 ; 68: 977-984. (Pubitemid 46569129)
6. Malucchi S., Gilli F., Caldano M., et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 2008 ; 70: 1119-1127.
7. Ross C., Clemmesen KM, Svenson M., et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann Neurol 2000 ; 48: 706-712.
8. Sorensen PS, Ross C., Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003 ; 362: 1184-1191.
9. Sorensen PS, Tscherning T., Mathiesen HK, et al. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology 2006 ; 67: 1681-1683.
10. Rio J., Nos C., Tintore M., et al. Assessment of different treatment failure criteria in a cohort of relapsingremitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol 2002 ; 52: 400-406.
11. Rio J., Nos C., Tintore M., et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006 ; 59: 344-352.
12. Rudick RA, Lee JC, Simon J., Ransohoff RM and Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004 ; 56: 548-555.
13. Sturzebecher S., Wandinger KP, Rosenwald A., et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 2003 ; 126: 1419-1429.
14. Villoslada P., Oksenberg JR, Rio J. and Montalban X. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2004 ; 62: 1653.
15. Waubant E., Vukusic S., Gignoux L., et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003 ; 61: 184-189.
16. Vinuesa CG, Tangye SG, Moser B. and Mackay CR Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol 2005 ; 5: 853-865.
17. Hoffmann S., Cepok S., Grummel V., et al. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 2008 ; 83: 219-227.
18. Stickler M., Valdes AM, Gebel W., et al. The HLA-DR2 haplotype is associated with an increased proliferative response to the immunodominant CD4(+) T-cell epitope in human interferon-beta. Genes Immun 2004 ; 5: 1-7.
19. Hemmer B., Stuve O., Kieseier B., Schellekens H. and Hartung HP Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol 2005 ; 4: 403-412.
20. Creagh EM and ONeill LA TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 2006 ; 27: 352-357.
21. Biragyn A., Ruffini PA, Leifer CA, et al. Toll-like receptor 4-dependent activation of dendritic cells by betadefensin 2. Science 2002 ; 298: 1025-1029.
22. Jiang D., Liang J., Fan J., et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005 ; 11: 1173-1179.
23. Park JS, Gamboni-Robertson F., He Q., et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006 ; 290: C917 - C924.
24. Akira S., Takeda K. and Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001 ; 2: 675-680. (Pubitemid 32747155)
25. Koch-Henriksen N. and Sorensen PS The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group. Mult Scler 2000 ; 6: 172-175.
26. Enevold C., Oturai AB, Sorensen PS, Ryder LP, Koch-Henriksen N and Bendtzen K. Multiple sclerosis and polymorphisms of innate pattern recognition receptors TLR1-10, NOD1-2, DDX58, and IFIH1. J Neuroimmunol 2009 ; 212 (1-2). 125-131.
27. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 ; 33: 1444-1452.
28. Bendtzen K. Anti-IFN BAb and NAb antibodies: a mini-review. Neurology 2003 ; 61 (9 ; Suppl 5). S6-10.
29. Sherry ST, Ward MH, Kholodov M., et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001 ; 29: 308-311.
30. The IIPGA database. http://www.innateimmunity.net/. Accessed February 2006.
31. The SNPper database. http://snpper.chip.org/bio/. Accessed February 2006.
32. Liu K. and Muse SV PowerMarker: an integrated analysis environment for genetic marker analysis. Bioinformatics 2005 ; 21: 2128-2129.
33. Guo SW and Thompson EA Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 1992 ; 48: 361-372.
34. Roxburgh RH, Seaman SR, Masterman T., et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005 ; 64: 1144-1151.
35. Alonso A., Jick SS, Olek MJ and Hernan MA Incidence of multiple sclerosis in the United Kingdom: findings from a population-based cohort. J Neurol 2007 ; 254: 1736-1741.
36. Compston A. The genetic epidemiology of multiple sclerosis. Philos Trans R Soc Lond B Biol Sci 1999 ; 354: 1623-1634.
37. Duquette P., Pleines J., Girard M., Charest L., Senecal-Quevillon M. and Masse C. The increased susceptibility of women to multiple sclerosis. Can J Neurol Sci 1992 ; 19: 466-471.
38. Nguyen LT, Ramanathan M., Weinstock-Guttman B., Baier M., Brownscheidle C. and Jacobs LD Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients. J Neurol Sci 2003 ; 209: 93-99.
39. Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006 ; 5: 932-936.
40. Byun E., Caillier SJ, Montalban X., et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008 ; 65: 337-344.
41. Comabella M., Craig DW, Morcillo-Suarez C., et al. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol 2009 ; 66: 972-978.
42. De Jager PL, Jia X., Wang J., et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009 ; 41: 776-782.
43. ODoherty C., Villoslada P. and Vandenbroeck K. Pharmacogenomics of Type I interferon therapy: a survey of response-modifying genes. Cytokine Growth Factor Rev 2007 ; 18: 211-222.
44. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996 ; 47: 889-894.
45. PRISMS-4. Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001 ; 56: 1628-1636.
46. Deisenhammer F. and Giovannoni G. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing/remitting multiple sclerosis. Mult Scler 2004 ; 10: 713-714.
47. Francis GS, Rice GP and Alsop JC Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005 ; 65: 48-55.
48. Kappos L., Clanet M., Sandberg-Wollheim M., et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005 ; 65: 40-47.
49. Petkau AJ, White RA, Ebers GC, et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004 ; 10: 126-138.
50. Deisenhammer F., Reindl M., Harvey J., Gasse T., Dilitz E. and Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999 ; 52: 1239-1243.
51. Goris A., Epplen C., Fiten P., et al. Analysis of an IFNgamma gene (IFNG) polymorphism in multiple sclerosis in Europe: effect of population structure on association with disease. J Interferon Cytokine Res 1999 ; 19: 1037-1046.
52. Goris A., Heggarty S., Marrosu MG, Graham C., Billiau A. and Vandenbroeck K. Linkage disequilibrium analysis of chromosome 12q14-15 in multiple sclerosis: delineation of a 118-kb interval around interferon-gamma (IFNG) that is involved in male versus female differential susceptibility. Genes Immun 2002 ; 3: 470-476.
53. Kantarci OH, Goris A., Hebrink DD, et al. IFNG polymorphisms are associated with gender differences in susceptibility to multiple sclerosis. Genes Immun 2005 ; 6: 153-161.
54. Vandenbroeck K., Opdenakker G., Goris A., Murru R., Billiau A. and Marrosu MG Interferon-gamma gene polymorphism-associated risk for multiple sclerosis in Sardinia. Ann Neurol 1998 ; 44: 841-842.
55. Kantarci OH, Hebrink DD, Schaefer-Klein J., et al. Interferon gamma allelic variants: sex-biased multiple sclerosis susceptibility and gene expression. Arch Neurol 2008 ; 65: 349-357.
56. Petereit HF, Nolden S., Schoppe S., Bamborschke S., Pukrop R. and Heiss WD Low interferon gamma producers are better treatment responders: a two-year follow-up of interferon beta-treated multiple sclerosis patients. Mult Scler 2002 ; 8: 492-494.
57. Dhiman N., Ovsyannikova IG, Vierkant RA, et al. Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. Vaccine 2008 ; 26: 1731-1736.
58. Trojano M., Pellegrini F., Paolicelli D., et al. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment. J Neurol Sci 2009 ; 286: 109-113.
59. Hayashi EA, Akira S. and Nobrega A. Role of TLR in B cell development: signaling through TLR4 promotes B cell maturation and is inhibited by TLR2. J Immunol 2005 ; 174: 6639-6647.
60. Ruprecht CR and Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 2006 ; 36: 810-816.
61. Kormann MS, Depner M., Hartl D., et al. Toll-like receptor heterodimer variants protect from childhood asthma. J Allergy Clin Immunol 2008 ; 122: 86-92.
62. Ma X., Liu Y., Gowen BB, Graviss EA, Clark AG and Musser JM Full-exon resequencing reveals toll-like receptor variants contribute to human susceptibility to tuberculosis disease. PLoS One 2007 ; 2: e1318.
63. Pierik M., Joossens S., Van SK, et al. Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis 2006 ; 12: 1-8.
64. Stevens VL, Hsing AW, Talbot JT, et al. Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk. Int J Cancer 2008 ; 123: 2644-2650.
65. Sun J., Wiklund F., Zheng SL, et al. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst 2005 ; 97: 525-532.
66. Tantisira K., Klimecki WT, Lazarus R., et al. Toll-like receptor 6 gene (TLR6): single-nucleotide polymorphism frequencies and preliminary association with the diagnosis of asthma. Genes Immun 2004 ; 5: 343-346.
67. Hornung V., Rothenfusser S., Britsch S., et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002 ; 168: 4531-4537.
68. Borsutzky S., Kretschmer K., Becker PD, et al. The mucosal adjuvant macrophage-activating lipopeptide-2 directly stimulates B lymphocytes via the TLR2 without the need of accessory cells. J Immunol 2005 ; 174: 6308-6313.
69. Ozinsky A., Underhill DM, Fontenot JD, et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA 2000 ; 97: 13766-13771.